Home›Companies›Biotech & Pharma›Evozyne

Evozyne, Inc.

Updated Oct 27, 2026·Latest SEC filing Sep 29, 2023·Suggest an edit

About Evozyne

Evozyne is a private company based in Chicago, Illinois, incorporated in 2019 in Delaware. It has reported $144,367,504 raised in three offerings on Form D since May 2020. Its chief executive is Mike Gamson.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 14, 2023Sep 29, 2023$81,000,122of $100.0M target29$2.7MEquity, DebtRule 506(b)Form D ↗
Apr 9, 2021Apr 22, 2021$54,183,709of $59.1M target12$4.5MEquityRule 506(b)Form D ↗
Apr 27, 2020May 7, 2020$9,183,673fully sold2$4.5MEquityRule 506(b)Form D ↗
Total, three offerings$144,367,504

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Evozyne's Form D filed Sep 29, 2023.

AT
Aris Theologis
Chief Business Officer
DP
Darien Parhad
Chief Financial Officer and Treasurer
JS
Jude Sullivan
General Counsel and Secretary
Also a general counsel and assistant secretary at Castle Creek Biosciences.
AL
Aleina Lee
Corporate Controller
RR
Rama Ranganathan
Chief Scientific Officer and Director
PM
Patrick Morris
Executive officer and director
Also a president, secretary and general counsel, director at CIRC Biosciences, a director at Castle Creek Biosciences and an executive vice president and secretary at Paragon Biosciences Emalex Capital.
MG
Mike Gamson
President, Chief Executive Officer, and Director
MR
AR
Arjun Rallapalli
Chief Operating Officer

Sources

  1. SECEvozyne, Inc. filing history